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INTRODUCTION
Prostate cancer (PCa) is the most common solid-organ malignancy and the second leading cause of cancer-related death in males (1) . In the vast majority of cases, PCa is diagnosed by a prostate biopsy (PBx) performed because of an elevated prostate-specific antigen (PSA) level and/or an abnormal digital rectal examination (DRE). In current clinical practice, however, the diagnostic yield of a first extended PBx is in the range of 40% (2) even selecting patients by "improved" nomograms (3).
Patients with an initial negative PBx have an approximately 20% incidence of PCa at a subsequent PBx (4) . While studies on saturation biopsy (5) provide evidence that the first PBx misses some of these cancers, studies on PCa chemoprevention (6, 7) demonstrate that other cancers may develop in the time span to second PBx due to progressive changes in the prostate microenvironment.
Chronic inflammation has been reported to cause as much as 20% of human cancers and to be implicated in prostate carcinogenesis by several mechanisms (8) . Basically, chronic inflammation creates a milieu rich in pro-inflammatory cytokines and growth factors that may lead to an uncontrolled proliferative response and genetic mutations of rapidly dividing cells (9, 10 ). An increased number of CD4 + CD25
+ and CD8 + Foxp3 + regulatory T cells cells have been observed in prostate glands and in the peripheral blood of PCa patients, suggesting an important role for active immune suppression of anti-tumor immunity (11-13).
Pentraxins, a superfamily of evolutionary conserved proteins, are essential components of the humoral arm of the innate immune system and play a pivotal role in vascular biology (14, 15) . Pentraxin-3 (PTX3), the prototype of long pentraxins, differs from short pentraxins for gene organization, cellular source and ligand-binding capacities (15, 16) .
Like short pentraxins, PTX3 facilitates dysregulation of mitogenic signalling pathways, sustains cellular proliferation, angiogenesis, insensitivity to apoptosis, cancer cell invasion and migration, and tumour escape from immunosurveillance (17, 18) . Unlike short pentraxins, such as C reactive protein (CRP), PTX3 is not produced by haepatocytes but synthesized by a variety of cell types at the site of inflammation (14, 19) , whereby it seems to regulate complement activation (14, 17, 18) . Recent findings suggest an insidious relationship between complement and cancer in terms of cellular proliferation and regeneration as well as angiogenesis (18, 20) .
Considering that chronic inflammation is found in as much as 80% of PBxs (7) and the potential role of PTX3 in inflammatory-related carcinogenesis (21) , the aim of present study was to determine whether PTX3 prostate tissue expression and serum levels could predict progression from chronic prostate inflammation to PCa. 
MATERIALS AND METHODS

Study population
Our institutional review board-approved prospective database on PBx was used to identify patients who were diagnosed with PCa by a second PBx performed at least one year after an initial negative PBx (Group A, n=20). A matched data set of patients with a second negative PBx performed at least one year after the first negative PBx (Group B, n=20) was created using a propensity score multidimensional matching technique based on the following clinical variables: age, serum PSA value, prostate volume, DRE findings, and time to second PBx. As previously described, all patients received, in the first and second PBx setting, a 18-core biopsy scheme following some form of local anesthesia (22, 23) .
Histologic analysis of prostatic tissue
Two senior uropathologists performed the analysis using contemporary diagnostic criteria for prostatic intraepithelial neoplasia (PIN), atypical small acinar proliferation (ASAP) and PCa. Moreover, biopsy samples of both benign prostatic tissue and PCa were graded on a 4-point scale for inflammation (0-no inflammatory cells, 1-scattered inflammatory cell infiltrate, 2-non-confluent lymphoid nodules and 3-large inflammatory areas with confluence of infiltrate) and aggressiveness (0-no contact between inflammatory cells and glandular epithelium; 1-contact between inflammatory cell infiltrate and glandular epithelium; 2-clear but limited, less than 25% of the examined material, glandular epithelium disruption, and 3-glandular epithelium disruption more than 25% of the examined material), as described by Irani et al. (24) . immune complexes were detected using the Alexa Fluor 488 goat anti-rat and 546 goat anti-mouse IgG (H+L) and goat anti-rabbit IgG antibodies (Molecular Probes, Eugene, OR), while nuclei were stained with TO-PRO-3 (Molecular Probes).
PTX3 ELISA
PTX3 serum levels were tested on serum samples drawn at the time of PBx in two independent groups of patients with biopsy-proven prostatic inflammation (n=61) and PCa (n=56). Serum samples, frozen at -80°C, were assayed in duplicate using a commercially available ELISA kit, according to manufacturer's instructions (R&D, Minneapolis, MN).
Statistical analysis
Statistical analyses were performed using SPSS software (SPSS 17.0 Inc., Evanston, IL).
Normal distribution of the data was evaluated by Skewness and Kurtosis test. Continuous variables were compared by paired or unpaired Student t-test, as appropriate. Correlation between two variables was ascertained by Pearson's correlation test. Frequencies were compared by the χ 2 test. To test the independent effects of different clinically relevant variables on histological diagnosis of PCa, a binary logistic regression analysis was used and serum levels PTX3, PSA and age were tested as covariates.
To validate the association of a variable with histological diagnosis, a Receiver operator characteristic curves (ROC) analysis was performed. An operational cut-off level was defined in order to differentiate the risk of PCa between the two groups.
A two-sided p<0.05 was considered statistically significant. Results were expressed in the text as mean ± standard deviation (SD) unless otherwise stated. 
RESULTS
Clinical and histological features
The main clinical features of the two sets of patients as well as the pathological features of cancers diagnosed at second PBx are summarized in Table 1 . There was no difference in the clinical and pathological characteristics of the two groups at the first PBx (Table 1) .
Tumor grading at the second biopsy in group A is reported in table 1.
PTX-3 protein prostatic tissue expression
In Group B, PTX3 protein expression was extremely low in both first and second PBx samples ( Fig. 1A and B) ; conversely, Group A showed a marked PTX3 protein expression already in the first PBx samples (Fig. 1C) , which further increased in the second PBx (Fig.   1D ). Specifically, patients in Group B had a statistically significantly lower PTX3 expression than those in Group A (Fig. 1E) Interestingly, double immunofluorescence confocal microscopy revealed that PTX3 extensively co-localized with PSA in both group A ( Fig. 2A-D) and group B biopsies ( Fig.   2E-H) . PTX 3 also co-localized with MPO + infiltrating cells, although they did not represent a major source of PTX3 within the prostate tissue (Fig. 3A-H) . On the other hand, CD4 + , or CD20 + infiltrating cells did not significantly express the long pentraxin ( Fig. 3I-X ).
PTX3 serum levels
Two independent groups of patients with biopsy-proven prostatic inflammation (n=61) and PCa (n=56) were recruited and PTX3 serum levels were assessed. The sample size of (Fig 4A) . Noteworthy, there was no difference in PSA serum levels (8.3±4.4 vs 7.5±3.7, ng/ml; p=0.7) between the two groups of patients (Fig 4B) .
To rule out the potential influence of systemic inflammation on PTX3 serum levels, we also tested CRP serum levels and found no difference between patients with prostatic inflammation 
Receiver operator characteristic curves (ROC) analysis.
A ROC curve analysis was carried out to further validate the association of PTX3 serum levels with the histological diagnosis of PCa and to define an operational cut-off value.
The analysis showed that PTX3 serum levels were significantly associated with PCa at PBx (AUC 0.922, p=0.0001), and defined a cut-off value of 3.25 ng/ml with a 88.5% 
specificity and a 89.3% sensitivity, a positive predictive value of 87.1% and a negative predictive value of 97.2% (Fig. 5A) . Moreover, serum PTX3 curve performed much better than the serum PSA curve (AUC 0.5569, p=0.3) (Fig. 5B ) and CRP curve (AUC 0.536, p=0.5) (Fig. 5C) . 
DISCUSSION
The present study demonstrates that PTX3 serum levels can reliably identify discriminate BPH from PCa. In addition, PTX3 tissue expression may also identify those patients with chronic inflammation at PBx who are at risk to develop PCa.
The potential role of PTX3 as a tissue and serum marker of carcinogenesis was recently postulated for human soft tissue liposarcoma (25) and lung carcinoma (20) . Serum PTX3 elevation in patients with cancer are not well understood, but its known over expression by endothelial cells and macrophages in response to inflammatory signals as well as its role in clearance of cells undergoing apoptosis (14) both suggest that PTX3 may act as a biomarker for neoplasia, through its elevation in the inflammatory microenvironment of the tumour and in the clearance of apoptotic cells (14) .
In this context the close relationship between complement cascade and PTX3 may represent an interesting pathogenic hypothesis. Indeed, there is a growing body of evidence linking a deregulation in complement cascade activation and carcinogenesis.
Prostate cancer cells are well known to express different regulatory proteins of the complement system and this event may represent a mechanism of tumour escape from complement-mediated immune surveillance (14) . PTX3 interaction with C1q result in complement activation on apoptotic cells whereas in the fluid phase induce inhibition of the complement cascade (17) . Since in our case PTX3 is released within the prostate tissue, as demonstrated by its increased circulating levels, it is conceivable that its overexpression may represent a further mechanism of prostate cancer escape from complement-mediated immunosurveillance. It has been shown that PTX3 may also directly restrict the cross-presentation of tumour-derived antigens, thus limiting the immune response towards cancer cells (26) . Conversely, our study demonstrated that PTX3 protein was significantly overexpressed in the prostate tissue of patients who developed PCa, as compared with those who did not, at both first and repeat PBx, thus representing a reliable immuno-histochemical marker to predict disease progression. Moreover, our study demonstrated that PTX3 serum levels were significantly higher in patients with PCa as compared with those with chronic prostatic inflammation, thus suggesting that PTX3 could become a reliable blood test for PCa diagnosis. Lack of correlation between PTX3 and CRP serum levels allowed to rule out the possibility of PTX3 increase being due to systemic inflammation, thus providing further support to the potential role of this marker in PCa development/progression.
Potential study limitations include its retrospective nature and the relatively small number of patients. Conversely, evaluation of inflammation at first and second PBx, demonstration of PTX3/PSA co-localisation, and correlation of PTX3 tissue expression with its serum levels certainly represent key strengths of our study.
In conclusion, the present study demonstrates for the first time that PTX3 prostatic tissue expression and PTX3 serum levels can reliably predict PCa development. These findings shed light on a potential molecular mechanism linking prostatic inflammation and carcinogenesis and provide solid grounds for further testing the predictive value of this biomarker as well as its potential to represent a target for PCa prevention. 
